点评：创新药收入强劲增长，现金流状况大幅改善：2023Q1-2024Q1，公司单季度营业收入分别为54.92/56.76/58.45/58.06/59.98亿元，同比+0.25%/19.51%/2.24%/8.93%/9.20%；归母净利润12.39/10.69/11.66/8.29/13.69亿元，同比+0.17%/21.17%/10.57%/13.05%/10.48%；扣非归母净利润12.20...
网页链接点评：创新药收入强劲增长，现金流状况大幅改善：2023Q1-2024Q1，公司单季度营业收入分别为54.92/56.76/58.45/58.06/59.98亿元，同比+0.25%/19.51%/2.24%/8.93%/9.20%；归母净利润12.39/10.69/11.66/8.29/13.69亿元，同比+0.17%/21.17%/10.57%/13.05%/10.48%；扣非归母净利润12.20...
网页链接
精彩评论